99 related articles for article (PubMed ID: 30711948)
41. Higher expression of peroxisome proliferator-activated receptor γ or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion.
Yang DR; Lin SJ; Ding XF; Miyamoto H; Messing E; Li LQ; Wang N; Chang C
Urology; 2013 May; 81(5):1109.e1-6. PubMed ID: 23522297
[TBL] [Abstract][Full Text] [Related]
42. B7‑H3 promotes malignant progression of muscle‑invasive bladder cancer.
Xu ZL; Zhang Y; Wang L; Li F; Man HW; Li PF; Shan BE
Oncol Rep; 2018 Nov; 40(5):2722-2733. PubMed ID: 30132557
[TBL] [Abstract][Full Text] [Related]
43. Divergent expression of bacterial wall sensing Toll-like receptors 2 and 4 in colorectal cancer.
Paarnio K; Väyrynen S; Klintrup K; Ohtonen P; Mäkinen MJ; Mäkelä J; Karttunen TJ
World J Gastroenterol; 2017 Jul; 23(26):4831-4838. PubMed ID: 28765705
[TBL] [Abstract][Full Text] [Related]
44. Toll-like receptor 4 promotes angiogenesis in pancreatic cancer via PI3K/AKT signaling.
Sun Y; Wu C; Ma J; Yang Y; Man X; Wu H; Li S
Exp Cell Res; 2016 Oct; 347(2):274-82. PubMed ID: 27426724
[TBL] [Abstract][Full Text] [Related]
45. Toll-like receptor 9 mediates invasion and predicts prognosis in squamous cell carcinoma of the mobile tongue.
Kauppila JH; Korvala J; Siirilä K; Manni M; Mäkinen LK; Hagström J; Atula T; Haglund C; Selander KS; Saarnio J; Karttunen TJ; Lehenkari PP; Salo T
J Oral Pathol Med; 2015 Sep; 44(8):571-7. PubMed ID: 25338738
[TBL] [Abstract][Full Text] [Related]
46. Immunohistochemical expression of TLR4 and TLR9 in various grades of oral epithelial dysplasia and squamous cell carcinoma, and their roles in tumor progression: a pilot study.
Kotrashetti VS; Nayak R; Bhat K; Hosmani J; Somannavar P
Biotech Histochem; 2013 Aug; 88(6):311-22. PubMed ID: 23651260
[TBL] [Abstract][Full Text] [Related]
47. Kindlin-2 expression in arsenite- and cadmium-transformed bladder cancer cell lines and in archival specimens of human bladder cancer.
Talaat S; Somji S; Toni C; Garrett SH; Zhou XD; Sens MA; Sens DA
Urology; 2011 Jun; 77(6):1507.e1-7. PubMed ID: 21624607
[TBL] [Abstract][Full Text] [Related]
48. An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancer.
Dancik GM
BMC Urol; 2015 Jul; 15():59. PubMed ID: 26126604
[TBL] [Abstract][Full Text] [Related]
49. Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer.
Wan YP; Xi M; He HC; Wan S; Hua W; Zen ZC; Liu YL; Zhou YL; Mo RJ; Zhuo YJ; Luo HW; Jiang FN; Zhong WD
Oncol Res Treat; 2017; 40(1-2):15-20. PubMed ID: 28118628
[TBL] [Abstract][Full Text] [Related]
50. Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling.
Kawakami K; Enokida H; Tachiwada T; Gotanda T; Tsuneyoshi K; Kubo H; Nishiyama K; Takiguchi M; Nakagawa M; Seki N
Oncol Rep; 2006 Sep; 16(3):521-31. PubMed ID: 16865252
[TBL] [Abstract][Full Text] [Related]
51. Controversial roles played by toll like receptor 4 in urinary bladder cancer; A systematic review.
Afsharimoghaddam A; Soleimani M; Lashay A; Dehghani M; Sepehri Z
Life Sci; 2016 Aug; 158():31-6. PubMed ID: 27316642
[TBL] [Abstract][Full Text] [Related]
52. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
[TBL] [Abstract][Full Text] [Related]
53. Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.
Lee MS; Lee J; Kim JH; Kim WT; Kim WJ; Ahn H; Park J
Oncotarget; 2015 Nov; 6(37):40370-84. PubMed ID: 26430961
[TBL] [Abstract][Full Text] [Related]
54. Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer.
Zhao XL; Zhao ZH; Xu WC; Hou JQ; Du XY
Int J Clin Exp Pathol; 2015; 8(2):1954-60. PubMed ID: 25973088
[TBL] [Abstract][Full Text] [Related]
55. Twist1 and Y-box-binding protein-1 are potential prognostic factors in bladder cancer.
Song YH; Shiota M; Yokomizo A; Uchiumi T; Kiyoshima K; Kuroiwa K; Oda Y; Naito S
Urol Oncol; 2014 Jan; 32(1):31.e1-7. PubMed ID: 23395237
[TBL] [Abstract][Full Text] [Related]
56. The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer.
Syring I; Weiten R; Müller T; Schmidt D; Steiner S; Kristiansen G; Müller SC; Ellinger J
Anticancer Res; 2017 Dec; 37(12):6685-6695. PubMed ID: 29187445
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of myeloid differentiation primary response 88 and Toll-like receptor 4 in breast cancer patients.
Ma FJ; Liu ZB; Hu X; Ling H; Li S; Wu J; Shao ZM
PLoS One; 2014; 9(10):e111639. PubMed ID: 25360699
[TBL] [Abstract][Full Text] [Related]
58. Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer.
Iliev R; Kleinova R; Juracek J; Dolezel J; Ozanova Z; Fedorko M; Pacik D; Svoboda M; Stanik M; Slaby O
Tumour Biol; 2016 Oct; 37(10):13385-13390. PubMed ID: 27460088
[TBL] [Abstract][Full Text] [Related]
59. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
[TBL] [Abstract][Full Text] [Related]
60. The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.
Li Z; Block MS; Vierkant RA; Fogarty ZC; Winham SJ; Visscher DW; Kalli KR; Wang C; Goode EL
Tumour Biol; 2016 Oct; 37(10):13279-13286. PubMed ID: 27460076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
